Adjuvant Chemotherapy for Colorectal Cancer

Dear Colleagues,

Management of colorectal cancer has substantially evolved over the last few decades. In addition to to the increased ability to dissect the biological complexity of this tumor, we have been able to gradually depart from the conventional “one-size-fit-all” approach and increasingly adopt molecular-based, risk-adapted treatment strategies. This paradigm shift, however, has especially concerned the management of advanced disease, whereas little progress has been made in the same direction with regard to the treatment of localized tumors. As a result, patient selection criteria and treatment strategies in the adjuvant setting have largely remained unchanged, with only some exceptions for rectal cancer.

Recently, we have witnessed a renewed awareness of the need to challenge the status quo in the management of early-stage colorectal cancer. Furthermore, significant interest has emerged for novel analytic techniques and risk-stratification tools that have the potential to represent real game changers in this context. Turning this premise into concrete advances in routine clinical practice is urgently needed, bearing in mind that approximately 75% of our patients present with nonmetastatic disease.

This Special Issue aims to provide readers with an overview of the current state of the art in the adjuvant chemotherapy treatment for colon and rectal cancers, as well as with valuable insights regarding the possible upcoming evolution of the same.

Dr. Francesco Sclafani
Dr. Giacomo Bregni
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.